Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

MONOCLONAL-ANTIBODY THERAPY WITH CICLOSPORIN AND STEROIDS IN NONMATCHED CADAVERIC RENAL-TRANSPLANTS NEPHRON Gordon, R. D., Starzl, T. E., Fung, J. J., Iwatsuki, S., Esquivel, C. O., Tzakis, A., Todo, S. 1987; 46: 56-59

Abstract

Thirty-six ciclosporin-prednisone-treated recipients of nonmatched cadaver renal allografts were given a course of Orthoclone OKT3 monoclonal antibody for steroid-resistant cell-mediated rejection. Although side effects were common, only 2 patients had to be withdrawn from therapy and there were no deaths related to therapy. Twenty-three (63.9%) allografts were rescued with OKT3 therapy and 21 (58.3%) of the grafts have continued to function well. We conclude that OKT3 is an effective agent for the treatment of steroid-resistant cell-mediated rejection and that rebound rejection can be prevented in most patients if adequate therapy with ciclosporin-prednisone is maintained.

View details for Web of Science ID A1987J437000009

View details for PubMedID 3306426

View details for PubMedCentralID PMC3005204